ADMA Biologics Inc
NASDAQ:ADMA
Balance Sheet
Balance Sheet Decomposition
ADMA Biologics Inc
ADMA Biologics Inc
Balance Sheet
ADMA Biologics Inc
| Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
13
|
26
|
17
|
10
|
10
|
43
|
23
|
27
|
56
|
51
|
87
|
51
|
103
|
|
| Cash Equivalents |
0
|
0
|
13
|
26
|
17
|
10
|
10
|
43
|
23
|
27
|
56
|
51
|
87
|
51
|
103
|
|
| Short-Term Investments |
0
|
0
|
0
|
3
|
5
|
6
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
4
|
1
|
4
|
13
|
29
|
16
|
27
|
50
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
4
|
1
|
4
|
13
|
29
|
16
|
27
|
50
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
3
|
1
|
1
|
2
|
2
|
3
|
5
|
13
|
19
|
53
|
82
|
125
|
163
|
173
|
170
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
2
|
3
|
3
|
4
|
5
|
5
|
8
|
|
| Total Current Assets |
4
|
1
|
14
|
31
|
24
|
21
|
22
|
62
|
45
|
86
|
154
|
209
|
270
|
257
|
331
|
|
| PP&E Net |
1
|
1
|
1
|
1
|
3
|
2
|
2
|
31
|
30
|
33
|
46
|
58
|
69
|
63
|
63
|
|
| PP&E Gross |
1
|
1
|
1
|
1
|
0
|
2
|
2
|
31
|
30
|
33
|
46
|
58
|
69
|
63
|
63
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
0
|
2
|
2
|
1
|
3
|
6
|
9
|
13
|
20
|
27
|
34
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
4
|
3
|
2
|
2
|
1
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
|
| Long-Term Investments |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
1
|
2
|
4
|
5
|
5
|
90
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
|
| Total Assets |
5
N/A
|
3
-44%
|
16
+438%
|
32
+105%
|
27
-16%
|
24
-12%
|
24
N/A
|
108
+356%
|
89
-18%
|
127
+43%
|
208
+63%
|
276
+33%
|
349
+26%
|
329
-6%
|
489
+48%
|
|
| Liabilities | ||||||||||||||||
| Accounts Payable |
1
|
1
|
1
|
3
|
2
|
2
|
3
|
6
|
6
|
9
|
11
|
12
|
13
|
16
|
20
|
|
| Accrued Liabilities |
1
|
1
|
1
|
1
|
2
|
2
|
2
|
3
|
4
|
5
|
9
|
17
|
24
|
31
|
30
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
7
|
1
|
0
|
0
|
0
|
0
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
5
|
|
| Total Current Liabilities |
9
|
2
|
2
|
4
|
4
|
4
|
11
|
9
|
10
|
14
|
20
|
30
|
39
|
50
|
56
|
|
| Long-Term Debt |
0
|
0
|
4
|
5
|
15
|
16
|
14
|
43
|
44
|
83
|
93
|
95
|
143
|
131
|
72
|
|
| Other Liabilities |
0
|
0
|
0
|
2
|
2
|
3
|
3
|
15
|
15
|
4
|
7
|
10
|
14
|
14
|
12
|
|
| Total Liabilities |
9
N/A
|
3
-73%
|
6
+144%
|
10
+70%
|
21
+102%
|
23
+9%
|
28
+23%
|
68
+141%
|
69
+2%
|
101
+46%
|
119
+18%
|
135
+13%
|
197
+45%
|
194
-1%
|
140
-28%
|
|
| Equity | ||||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
24
|
30
|
37
|
53
|
69
|
87
|
107
|
151
|
216
|
265
|
341
|
412
|
478
|
506
|
309
|
|
| Additional Paid In Capital |
20
|
30
|
47
|
74
|
76
|
88
|
103
|
191
|
236
|
291
|
429
|
553
|
630
|
641
|
658
|
|
| Total Equity |
4
N/A
|
0
N/A
|
9
+2 250%
|
22
+130%
|
6
-72%
|
1
-87%
|
5
N/A
|
40
N/A
|
20
-51%
|
26
+32%
|
88
+237%
|
141
+60%
|
152
+8%
|
135
-11%
|
349
+158%
|
|
| Total Liabilities & Equity |
5
N/A
|
3
-44%
|
16
+438%
|
32
+105%
|
27
-16%
|
24
-12%
|
24
N/A
|
108
+356%
|
89
-18%
|
127
+43%
|
208
+63%
|
276
+33%
|
349
+26%
|
329
-6%
|
489
+48%
|
|
| Shares Outstanding | ||||||||||||||||
| Common Shares Outstanding |
2
|
4
|
6
|
9
|
9
|
11
|
13
|
37
|
46
|
59
|
105
|
196
|
222
|
226
|
237
|
|
| Preferred Shares Outstanding |
3
|
8
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|